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Fig. 1 (abstract O25). Response rate for each outcome measure.
Responders ≥ 30% improvement on each outcome measure; ≥3
HIT-6 points improvement. HA: headache, SPO: subjective
perceived outcome
Table 1 (abstract O25). Results of univariate and multivariate analysis
Variables Univariable Analysis
r2
Multivariable Analysis
β, Standard error
p=value
Change in headache days 0.292 1.126, 0.120 0.294
Change in pain intensity 0.488 0.539, 0.090 <0.001
Change in pain duration 0.303 0.194, 0.083 0.022
HIT-6 points 0.130 0.216, 0.217 0.321
Dependent Variable: Patient subjective perceived outcome (SPO)O25
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Introduction
OnabotulinumtoxinA is standard care of management for chronic mi-
graine (CM). Few studies on the use of OnabotulinumtoxinA on CM
have identified factors associated with a positive response to Onabo-
tulinumtoxinA treatment. There are currently no data on outcome
measures that might predict subjective perceived outcome (SPO) to
OnabotulinumtoxinA in reported by patients with medically-
refractory chronic migraine (rCM).
Aim
To identify components of headache characteristics (frequency, in-
tensity, duration) or disability score (Headache Impact Test-6, HIT-6)
that predicts SPO.Method
100 patients who had completed at least two full treatment cycles
and had at least six months follow up were identified. Data on SPO,
clinical and headache characteristics were collected prospectively on
all patients using headache diaries, feedback forms and validated dis-
ability scores. Variables analysed for predictors of SPO were head-
ache characteristics (frequency, intensity and duration) and disability
score (HIT-6) using multivariate analysis.
Results
Response rates are shown in Fig. 1. Multivariate analysis showed
change in pain intensity (p<0.001) and pain duration (p=0.022) were
significantly positively associated with SPO. Change in headache days
(p=0.294) and HIT-6 score (p=0.321) were not significantly positively
associated with SPO. Table 1 shows results of multivariate analysis.
Conclusion
Our data suggest that improvement in pain intensity and headache
duration predicts SPO to onabotulinumtoxinA in rCM. The results of
this study suggest that for rCM the use of pain intensity and head-
ache duration appear to be the more appropriate outcome measure
to assess. The current NICE guidelines which state that response
should be assessed using headache days alone may not be appropri-
ate for rCM.
